{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-047061","form_type":"8-K","ticker":null,"cik":"0001124804","company_name":"Veradigm Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.456077+00:00","generated_at":"2026-06-05T10:39:50.444374+00:00","sec_items":["1.01","3.03","2.02","3.01","3.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Veradigm to acquire ScienceIO for $140M; expects Nasdaq delisting","bullets":["Merger to acquire ScienceIO for $140M cash, with $43.55M deferred over three years.","Anticipates Nasdaq delisting after failing to file 2022 10-K and 2023 Q reports by Feb 27 deadline.","Board adopted stockholder rights plan (poison pill) with 20% threshold for passive investors, 10% for active.","Issued preliminary unaudited FY2023 financial results; specific figures not in filing text.","Up to 2,750,000 RSUs granted to ScienceIO employees as retention pool, vesting over four years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-047061","json":"https://secwatch.observer/filing/0001193125-24-047061.json","markdown":"https://secwatch.observer/filing/0001193125-24-047061.md","text":"https://secwatch.observer/filing/0001193125-24-047061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124804/000119312524047061/0001193125-24-047061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124804/000119312524047061/d793739d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:39:50.444374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f07d79ef21d6f66b24bd6ca3337d5281fecc168","claim":"Veradigm Inc. reported preliminary financial results for fiscal 2023.","evidence_excerpt":"On February 27, 2024, the Company issued a press release regarding the transactions contemplated by the Merger Agreement and containing certain estimated, unaudited financial information relating to the fiscal 2023 reporting period (collectively, the “Financial Information”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124804/000119312524047061/0001193125-24-047061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"0e49e886063e19fca2b1fe57e4295399f4e9c720","claim":"Veradigm Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"February 27, 2024, the Company announced that, because the Company does not expect to have filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) or its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 (the “Q1 Form 10-Q”), June 30, 2023 (the “Q2 Form 10-Q”) and September 30, 2023 (together with the Q1 Form 10-Q and the Q2 Form 10-Q, the “Form 10-Qs”) on or before the deadline that The Nasdaq Hearings Panel (the “Panel”) had given the Company to regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company anticipates that it will r","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124804/000119312524047061/0001193125-24-047061-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"72e415c9b4b0359f31a2948202a8151a9f67082a","claim":"Veradigm Inc. entered into Agreement and Plan of Merger with Cascade Bio, Inc. d/b/a ScienceIO valued at $140,000,000 (effective 2024-02-21).","evidence_excerpt":"On February 21, 2024, Veradigm Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Cascade Bio, Inc., a Delaware corporation d/b/a ScienceIO (“ScienceIO”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124804/000119312524047061/0001193125-24-047061-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Cascade Bio, Inc. d/b/a ScienceIO"},{"label":"Value","value":"$140,000,000"},{"label":"Effective","value":"2024-02-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}